The subsequent EPIC‐CAD trial from Korea showed that edoxaban monotherapy was superior in net adverse clinical events, consisting of all‐cause death, MI, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding, to the antithrombotic regimen of edoxaban plus SAPT (either aspirin or P2Y12 inhibitor) in patients with AF and CAD, mainly driven by a reduction in bleeding outcomes [22]. The gene discussed is P2RY12; the disease is stroke disorder.